• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cosmos Health Inc (NQ: COSM )

    0.7089 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EDT, Apr 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 105
    Open 0.7089
    Bid (Size) 0.6753 (16)
    Ask (Size) 0.7090 (1)
    Prev. Close 0.7089
    Today's Range 0.7089 - 0.7089
    52wk Range 0.4677 - 3.440
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
    Via ACCESSWIRE

    Performance

    YTD
    -48.26%
    -48.26%
    1 Month
    +1.27%
    +1.27%
    3 Month
    -37.82%
    -37.82%
    6 Month
    -31.17%
    -31.17%
    1 Year
    -77.06%
    -77.06%

    More News

    Read More
    Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
    Via ACCESSWIRE
    Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market
    Via ACCESSWIRE
    Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders
    Via ACCESSWIRE
    Cosmos Health Successfully Completes Acquisition of Pharmatrade’s Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million
    Via ACCESSWIRE
    Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price
    Via ACCESSWIRE
    Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Taglich Brothers Initiates Coverage of Cosmos Health Inc.
    Via ACCESSWIRE
    Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market
    Via ACCESSWIRE
    Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
    Via ACCESSWIRE
    Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023
    Via ACCESSWIRE
    Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X
    Via ACCESSWIRE
    Cosmos Health Announces Open Market Stock Purchases by the CEO
    Via ACCESSWIRE
    Cosmos Health to Participate at Capital Link’s 'Invest in Greece' Forum in New York
    Via ACCESSWIRE
    Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers
    Via ACCESSWIRE
    Cosmos Health Announces Patent Filing for its Obesity and Weight Management Product
    Via ACCESSWIRE
    Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
    Via ACCESSWIRE
    Over $5M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying
    Via Benzinga
    Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders
    Via ACCESSWIRE
    COSMOS HEALTH CEO Issues Letter to Shareholders
    Via ACCESSWIRE
    Ticking Time Bombs: 3 Healthcare Stocks to Dump Before the Damage Is Done
    Via InvestorPlace
    Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.